No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
Nihon Chouzai Co., Ltd. is a Japanese enterprise primarily known for operating a vast network of health insurance-compliant dispensing pharmacies throughout the country. Beyond its core retail pharmacy business, the company develops and markets generic medications, supplying them to various medical facilities and other drug retailers. It also provides diverse human resources solutions, including temporary staffing for pharmacists and recruitment services for medical doctors, licensed sales personnel, and other professionals within the healthcare industry. Additionally, Nihon Chouzai offers specialized research and study services to pharmaceutical companies and related organizations, alongside providing expert information and consulting to the broader pharmaceutical and healthcare sectors. A range of other services are also part of its portfolio. As of March 31, 2022, the company operated 697 stores. Established in 1980, its corporate headquarters are located in Tokyo, Japan.
www.nicho.co.jpNo one on the platform currently holds 3341.T.
No tracked institution reports a position in 3341.T as of their last filing.
No one on the platform has traded 3341.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 3.4% | 4.6% | 5.4% | — | — | — |
| Rev. Growth % | 5.9% | 6.1% | ||||
| Profit Margin % | 0.4% | 1.0% | 1.7% | |||
| Free Cash Flow Margin % | 0.7% | 2.3% | 1.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $408.3B | +6.4% | $170.50 | $170.50–$170.50 | — | 1 |
| 2028 | $417.8B | +2.3% | $168.10 | $168.10–$168.10 | — | 1 |
| 2029 | $433.5B | +3.8% | $193.00 | $193.00–$193.00 | — | 1 |
| 2030 | $445.1B | +2.7% | $219.00 | $219.00–$219.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| +0.00% |
| $143.6B |
| — |
| 4534.TMochida Pharmaceutical Co., Ltd. | $3250.00 | +0.78% | $114.9B | — |
| 4694.TBML, Inc. | $3640.00 | +0.69% | $136.4B | — |
Source: Financial Modeling Prep · peers by sector/industry